This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views
Leukemia Open Access 03 September 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Heidel FH, Al-Ali H-K, Hirt C, Kampfe D, Jentsch-Ullrich K, Junghanss C, et al. Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions. Leukemia 2018. [Epub ahead of print]
Barbui T, Passamonti F, Accorsi P, Pane F, Vannucchi AM, Velati C, et al. Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera. Leukemia. 2018. [Epub ahead of print]
Alonso-Coello P, Schünemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ. 2016;353:i2016.
Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ. 2016;353:i2089.
Barosi G, Gale RP Is there expert consensus on expert consensus? Bone Marrow Transplant 2018. [Epub ahead of print]
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
GB received advisory board funds from Novartis. FP received advisory board funds from Novartis, Roche and Janssen and speaker bureau funds from Novartis, Sandoz, Janssen and Celgene. PA received a research grant from Sanofi. FP received speaker bureau funds from Novartis. AMV received a fund from Novartis for an advisory board and for research. RPG is a part-time employee of Celgene Corp. TB received advisory board funds from Novartis. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Rights and permissions
About this article
Cite this article
Barosi, G., Passamonti, F., Accorsi, P. et al. Response to “Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions” by Heidel et al.. Leukemia 32, 2727–2728 (2018). https://doi.org/10.1038/s41375-018-0259-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-018-0259-x